Advisory Services Network, LLC Ligand Pharmaceuticals Inc Transaction History

Advisory Services Network, LLC

$4.9 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$49.57 - $72.63 $5,551 - $8,134	112 New	112 $7,000
Q1 2023 May 17, 2023	BUY	$65.67 - $77.08 $459 - $539	7 Added 6.25%	119 $8,000
Q4 2022 Feb 13, 2023	BUY	$61.72 - $96.74 $6,912 - $10,834	112 New	112 $7,000
Q3 2021 Nov 05, 2021	SELL	$102.33 - $144.73 $11,460 - $16,209	-112 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$113.03 - $155.64 $12,659 - $17,431	112 New	112 $15,000
Q1 2021 May 24, 2021	SELL	$99.52 - $215.83 $16,122 - $34,964	-162 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$80.55 - $106.05 $161 - $212	-2 Reduced 1.22%	162 $16,000
Q3 2020 Nov 16, 2020	BUY	$89.56 - $126.72 $14,687 - $20,782	164 New	164 $15,000
Q2 2020 Aug 10, 2020	SELL	$68.28 - $123.65 $14,475 - $26,213	-212 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$63.37 - $107.88 $4,879 - $8,306	-77 Reduced 26.64%	212 $15,000
Q4 2019 Feb 04, 2020	SELL	$96.94 - $113.59 $7,173 - $8,405	-74 Reduced 20.39%	289 $30,000
Q2 2019 Aug 01, 2019	SELL	$107.38 - $129.34 $22,335 - $26,902	-208 Reduced 36.43%	363 $0
Q1 2019 May 20, 2019	SELL	$105.93 - $142.47 $1,165 - $1,567	-11 Reduced 1.89%	571 $72,000
Q4 2018 Feb 15, 2019	BUY	$128.36 - $272.13 $898 - $1,904	7 Added 1.22%	582 $79,000
Q3 2018 Nov 02, 2018	SELL	$211.18 - $274.49 $4,857 - $6,313	-23 Reduced 3.85%	575 $158,000
Q2 2018 Jul 27, 2018	SELL	$150.77 - $207.98 $301 - $415	-2 Reduced 0.33%	598 $139,000
Q1 2018 Apr 23, 2018	BUY	$138.63 - $182.62 $1,247 - $1,643	9 Added 1.52%	600 $0
Q4 2017 Feb 08, 2018	BUY	$128.36 - $147.04 $57,762 - $66,168	450 Added 319.15%	591 $81,000
Q2 2017 Aug 17, 2017	BUY	N/A	141	141 $17,000

Others Institutions Holding LGND

# of Institutions

257

Shares Held

18.2M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.02B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisory Services Network, LLC with notifications on news.

Account